Global Human Insulin Market Share Likely to Expand At a CAGR of 8% By 2033

According to Custom Market Insights (CMI), the human insulin market presented an earning of USD 44 billion by the year 2021 and is foreseen to touch USD 70.68 billion by the end of 2030 at a compound annual growth rate of 8%. The number of patients suffering from diabetes has increased tremendously over a period of time as a result of the rapid modernization which has taken place all over the world.

Diabetes has become a very common disease among people of all age groups and hence these medicines have experienced a huge demand from the current market. As these medicines create habits in the body of the individual, the market experiences an increasing demand over a period of time. The use of advanced medicines with the view to control and manage diabetes in a more efficient manner helps the market to record considerable revenue over the period of time. Diabetes has become a very common disease among children as well which has boosted the market for human insulin to a great extent.

Browse the full “Human Insulin Market Size, Trends and Insights By Type (Modern Human Insulin, Traditional Human Insulin), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Type of Diabetes (Diabetes Type 1, Diabetes Type 2), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032” report at https://www.custommarketinsights.com/report/human-insulin-market/

Regional Snapshots

The geographical sector of North America has proved to be the largest market for human insulin with a huge population that falls under the category of diabetic patients. The increasing prevalence of obesity which results from sedentary lifestyle practices and faulty food habits has boosted the number of cases suffering from diabetes.

The huge number of complications that are associated with this disease has also boosted the demand for advanced human insulin options. Human insulin is a very common medicine that is used for diabetic patients in order to control their sugar levels quickly with a view to stabilizing the condition of the patient.

The region of Europe has also experienced a huge demand for human insulin pertaining to the vast client base existing in this region. The modern health care facilities which are provided to the people by the government have boosted the market for human insulin to a great extent. The reason the Asia Pacific has experienced tremendous growth in the human insulin market owing to the increasing number of patience belonging to this region.

Market Dynamics

Drivers

The sedentary lifestyle practices have increased the number of people suffering from obesity and cholesterol which behave as the major causative factors for developing diabetes. Increasing demand for modern medicine and acceptance among the people for advanced technology has boosted the market for human insulin. The introduction of new medicines into the market which has better results regarding the management of diabetes has boosted the sales and demand for insulin in the market. These factors help to drive the market to greater heights over a period of time.

Restraints

The high cost associated with diabetic medicines and insulin has proved to be an obstacle to the growth of the human insulin market. The habit-forming feature of diabetic medicines has restrained the growth of the human insulin market. Chronic use of chemically formatted medicines hampers the health of the individual which proves to be an obstacle for the market. These reasons have hampered the growth of the market tremendously.

Opportunities

The huge number of people suffering from diabetes is itself a big opportunity for the developing market. The rise in the number of old people all over the world has increased the number of diabetic patients to a great extent. Modern lifestyle practices are a major causative factor of diabetes due to the high amount of sugar and chemicals contained in foods and beverages. These reasons have provided the key market players with great opportunities.

Challenges

The varying cost of diabetic medicines has challenged the demand and supply chain of the market. The side effects associated with the use of modern medicine have hindered the growth of the market to a great extent. Increasing competition among the key market players in order to introduce advanced medicines to capture the market has confused the consumers regarding the proper selection of medicines. These multiple factors have challenged the growth of the human insulin market to a great extent.

Report Scope

Report Highlights

On the basis of type, the modern human insulin has presented a huge market size pertaining to the increasing demand for modern medicine and rapidly increasing acceptance of advanced technologies. The huge number of cases all over the world has boosted the demand for modern insulin options which provide patients with better diabetes management and a lesser number of side effects and complications. On basis of the type of diabetes, type 1 diabetes has become the most common type among people all over the world, especially in the region of North America and the Asia Pacific countries.

The prevalence of type 2 diabetes has been seen in the European nations. On the basis of distribution channels, online pharmacies have shown tremendous growth as a result of the increasing trend of online shopping which helps the consumer to enjoy all the facilities by staying in their own comfort zone. The people belonging to the elderly age group are benefit from the help of these facilities which makes them self-reliant and independent.

Online pharmacies help patients to choose and select from a wide range of medicines according to their properties, cost, and quality. The segment of hospital pharmacies has also experienced tremendous growth pertaining to the huge number of people visiting this sector for the management of their diabetic profiles and regular checkups.

The retail pharmacy stores have shown considerable growth due to the presence of the local crowd around them who prefer to avoid the expenses of hospitals and purchase medicines directly over the counter based on the previous prescriptions provided at the hospitals. On the basis of geography, the North American market has shown tremendous growth as a result of the huge population suffering from diabetes and the growing disposable income of the people which makes it possible for them to purchase these advanced medicines.

Key Market Players

• Novo Nordisk A/S
• Eli Lilly and Company
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• ADOCIA
• Sanofi
• Biocon
• Wockhardt
• Julphar
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Pfizer, Inc.
• Oramed Pharmaceuticals, Inc.

Recent Developments

Insulin Lispro was conducted by Eli Lily and the company in the form of a generic version of Humalog in the year 2019 at a very minimal price which amounted to around 50 percent of its existing value.

Segments covered under the Human Insulin Market

By Type

• Modern Human Insulin
• Traditional Human Insulin

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Type of Diabetes

• Diabetes Type 1
• Diabetes Type 2

On the basis of Geography

North America

• The U.S.
• Canada
• Mexico

Europe

• France
• The UK
• Spain
• Germany
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America